- Home
- SGMO vs BMN Comparison
SGMO vs BMN Comparison
Compare SGMO & BMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SGMO | BMN |
|---|---|---|
| Founded | 1995 | 2020 |
| Country | United States | United States |
| Employees | N/A | 19800 |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 155.1M | 151.8M |
| IPO Year | 2000 | N/A |
Fundamental Metrics
Financial Performance| Metric | SGMO | BMN |
|---|---|---|
| Price | $0.50 | $25.32 |
| Analyst Decision | Buy | |
| Analyst Count | 7 | 0 |
| Target Price | ★ $4.71 | N/A |
| AVG Volume (30 Days) | ★ 9.3M | 29.9K |
| Earning Date | 11-06-2025 | 01-01-0001 |
| Dividend Yield | N/A | ★ 4.66% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $32,875,000.00 | N/A |
| Revenue This Year | $1.37 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.38 | $21.51 |
| 52 Week High | $2.84 | $25.59 |
Technical Indicators
Market Signals| Indicator | SGMO | BMN |
|---|---|---|
| Relative Strength Index (RSI) | 51.55 | 67.66 |
| Support Level | $0.42 | $24.74 |
| Resistance Level | $0.55 | $24.84 |
| Average True Range (ATR) | 0.05 | 0.22 |
| MACD | 0.02 | 0.06 |
| Stochastic Oscillator | 67.23 | 93.48 |
Price Performance
Historical ComparisonAbout SGMO Sangamo Therapeutics Inc.
Sangamo Therapeutics Inc is a genomic medicine company committed to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious neurological diseases. Its pipeline products include the Priority Neurology Pipeline offers Chronic Neuropathic Pain, Prion Disease, and Neurology; Partnered Programs offer Hemophilia A, Oncology, ALS/FTD, and Huntington's Disease; and Other Pipelines include Fabry Disease, Renal Transplant, Inflammatory Bowel Disease, and Multiple Sclerosis.
About BMN BlackRock 2037 Municipal Target Term Trust of Beneficial Interest
BlackRock 2037 Mun Tgt is a non-diversified, closed-end management investment company. The Trust's investment objective is to provide current income that is exempt from regular federal income tax. The Trust invests in investment grade quality securities or securities that are unrated but judged to be of comparable quality by the investment adviser.